Study Summary
This trial is studying CIML NK cells plus IL-2 in treating patients with acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms who have relapsed after stem cell transplantation.
- Acute Myeloid Leukemia
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
- Juvenile Myelomonocytic Leukemia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 11 Secondary · Reporting Duration: 1 Year
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
CIML NK
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: CIML NK · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Shapiro, Roman M., Grace C. Birch, Guangan Hu, Juliana Vergara Cadavid, Sarah Nikiforow, Joanna Baginska, Alaa K. Ali, et al.. 2022. “Expansion, Persistence, and Efficacy of Donor Memory-like NK Cells Infused for Posttransplant Relapse”. Journal of Clinical Investigation. American Society for Clinical Investigation. doi:10.1172/jci154334.
- Shapiro, Roman M., Grace C. Birch, Guangan Hu, Juliana Vergara Cadavid, Sarah Nikiforow, Joanna Baginska, Alaa K. Ali, et al.. 2022. “Expansion, Persistence, and Efficacy of Donor Memory-like NK Cells Infused for Posttransplant Relapse”. Journal of Clinical Investigation. American Society for Clinical Investigation. doi:10.1172/jci154334.
- Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, Rambaldi B, Arihara Y, Reynolds C, Halpern MS, Rodig SJ, Cullen N, Wolff JO, Pfaff KL, Lane AA, Lindsley RC, Cutler CS, Antin JH, Ho VT, Koreth J, Gooptu M, Kim HT, Malmberg KJ, Wu CJ, Chen J, Soiffer RJ, Ritz J, Romee R. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 Jun 1;132(11):e154334. doi: 10.1172/JCI154334.
- Roman Shapiro, MD 2019. "A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04024761.
Frequently Asked Questions
What is the scope of patients participating in this clinical trial?
"Affirmative. Per the details published on clinicaltrials.gov, this research project is actively recruiting participants and was last updated on June 15th 2022. 50 individuals shall be sourced from two sites for inclusion in the study; it first opened to applicants back on August 31st 2019." - Anonymous Online Contributor
What have been the major findings of research concerning CIML NK?
"At present, 889 live studies are being conducted on CIML NK. Out of these research operations, 161 have reached the advanced Phase 3 stage. While a majority of trials occur in Philadelphia, Pennsylvania - 28443 sites around the world are running experiments with this drug treatment." - Anonymous Online Contributor
What evidence exists to demonstrate the safety of CIML NK for patients?
"There is only a small amount of evidence attesting to the safety and efficacy of CIML NK, thus it received an assessment of 1." - Anonymous Online Contributor
What symptoms have been addressed most often with CIML NK therapy?
"CIML NK is a popular medication for the treatment of multiple sclerosis, but it may also be efficacious in treating conditions such as mixed-cell type lymphoma, leukemia, myelocytic acute and retinoblastoma." - Anonymous Online Contributor
Are there any available openings for participants in this research?
"Affirmative. Clinicaltrials.gov suggests that this research study is still searching for participants, which was first made known on August 31st 2019 and has been revised as of June 15th 2022. The trial necessitates 50 people to be enrolled from two separate medical sites." - Anonymous Online Contributor